Bravado Pharmaceuticals, LLC, of Lutz Florida, is pleased to announce a collaboration with SPARKGLOBAL “translational scientists without borders”.
From the SPARK website “SPARK is a unique partnership between university and industry founded by Professor Daria Mochly-Rosen in 2006 at Stanford University in USA. The purpose is to provide the education and mentorship necessary to advance research discoveries from the bench to the bedside. SPARK provides access to specialized knowledge and technical expertise regarding drug and diagnostic development and sources of funding to support translational efforts.”
“The MISSION of SPARK is to improve human health by uniting academics and industry experts around the globe to generate an efficient, effective and exiting pathway for translation of academic discoveries and innovative solutions through education and project support”.
Led by Professor Daria Mochly Rosen, Bravado and SPARK have been working together since late May to develop a novel Nasal Antibody Drop system “CoVer”.
The formulation forms an antibody blockade preventing CV19 from entering through the nasal cavity where it binds to the ACE receptor. Initial prototypes show extreme promise and phase I material was manufactured at the Bravado site in early Fall 2020. Brian McMillan, President and CEO of Bravado said, “the ability of Bravado to clinical manufacture a sterile product and ship to the clinic in Sydney Australia just months after opening it’s doors 02 Mar 2020 amidst the Covid 19 crisis is an incredible accomplishment on the part of our TEAM”.
The Global group includes: SPARK Africa, SPARK Americas, SPARK Asia, SPARK Europe and SPARK Oceania